Qiagen N.V. Common Shares (QGEN) closed at $50.30 on November 11, 2026, down 0.4% from the previous close, on volume of 2,043,046 shares (30-day average 5,052,852).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Call Spread | 20-Nov-2650 : 55 C | 3,066 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Bank of America Reports 5.50% QIAGEN Stake
TipRanks (Tue, 10-Nov 4:29 PM ET)
AFM Register Reports T. Rowe Price’s 3.03% QIAGEN Interest
TipRanks (Tue, 10-Nov 4:29 PM ET)
T. Rowe Price Group Reports 2.98% Capital Interest in QIAGEN
TipRanks (Tue, 10-Nov 4:29 PM ET)
AFM Publishes BlackRock Voting Rights Notification for Qiagen
TipRanks (Tue, 10-Nov 4:28 PM ET)
Amundi Notification Reports 3.25% Capital Interest in QIAGEN
TipRanks (Tue, 10-Nov 4:28 PM ET)
AFM Register Records UBS Group’s 5.46% QIAGEN Capital Interest
TipRanks (Tue, 10-Nov 4:28 PM ET)
AFM Discloses BlackRock Voting-Rights Notification for Qiagen
TipRanks (Tue, 10-Nov 4:27 PM ET)
AFM Discloses UBS Group Voting-Rights Notification for Qiagen
TipRanks (Tue, 10-Nov 4:27 PM ET)
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
Business Wire (Fri, 6-Nov 10:00 AM ET)
QIAGEN Reports Full Q3 2026 Results
Business Wire (Wed, 4-Nov 4:05 PM ET)
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of November 12, 2026, QGEN stock price declined to $50.09 with 2,093,594 million shares trading.
QGEN has a beta of 0.44, meaning it tends to be less sensitive to market movements. QGEN has a correlation of 0.02 to the broad based SPY ETF.
QGEN has a market cap of $10.34 billion. This is considered a Large Cap stock.
Last quarter Qiagen N.V. Common Shares reported $548 million in Revenue and $.65 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.02.
In the last 3 years, QGEN traded as high as $57.82 and as low as $32.53.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, FXH, IWS, FMDE.
QGEN has outperformed the market in the last year with a price return of +19.2% while the SPY ETF gained +12.4%. QGEN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.4% and -0.5%, respectively, while the SPY returned -1.1% and -1.6%, respectively.
QGEN support price is $49.55 and resistance is $51.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN shares will trade within this expected range on the day.
